1-(2-甲基-5-硝基苯基)硫脲 | 372198-70-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(2-甲基-5-硝基苯基)硫脲
• 英文名称: 1-(2-methyl-5-nitrophenyl)thiourea
• 英文别名: (2-Methyl-5-nitrophenyl)thiourea
• CAS: 372198-70-4
• 化学式: C₈H₉N₃O₂S
• mdl: MFCD02727443
• 分子量: 211.244
• InChiKey: BOZLXCILDJZHSR-UHFFFAOYSA-N

物化性质

• 熔点：
  55-56 °C
• 沸点：
  357.5±52.0 °C(Predicted)
• 密度：
  1.450±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-甲基-5-硝基苯基)硫脲 在 tin(II) chloride dihdyrate 、 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-((dimethylamino)methyl)-N-(3-((4-(4-(di-tertbutoxycarbonylamino)pyrimidin-2-yl)thiazol-2-yl)amino)-4-methylphenyl)benzamide
  参考文献：
  名称：

  [EN] DEOXYCYTIDINE KINASE INHIBITORS
  [FR] INHIBITEURS DE DÉSOXYCYTIDINE KINASE

  摘要：

  The present invention relates to compounds of formula (I) as deoxycytidine kinase inhibitors and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for treating a cancer.

  公开号：

  WO2023135330A1
• 作为产物：
  描述：

  N-[(2-methyl-5-nitrophenyl)carbamothioyl]benzamide 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 6.0h， 以95%的产率得到1-(2-甲基-5-硝基苯基)硫脲
  参考文献：
  名称：

  Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases

  摘要：

  Inhibitors of histone deacetylases are a new class of cancer therapeutics with possibly broad applicability. Combinations of HDAC inhibitors with the kinase inhibitor 1 (Imatimb) in recent studies showed additive and synergistic effects. Here we present a new concept by combining inhibition of protein kinases and HDACs, two independent pharmacological activities, in one synthetic small molecule. In general, the HDAC inhibition profile, the potencies, and the probable binding modes to HDAC1 and HDAC6 were similar as for 6 (SAHA). Inhibition of AN kinase in biochemical assays was maintained for Most compounds, but in general the kinase selectivity profile differed from that of I with nearly equipotent inhibition of the wildtype and the Imatimb resistant Abl (TI)-I-315 mutant. A potent cellular inhibition of PDGFR and cytotoxicity toward EOL-1 cells, a model for idiopathic hypereosinophilic syndrome (HES), are restored or enhanced for selected analogues (12b, 14b, and 18b). Cytotoxicity was evaluated by using a broad panel Of tumor cell lines, with selected analogues displaying mean IC50 values between 3.6 and 7.1 mu M.

  DOI：

  10.1021/jm800988r

文献信息

• 一种新型苯甲酰胺类化合物
  申请人：正大天晴药业集团股份有限公司

  公开号：CN103130791B

  公开（公告）日：2016-05-04

  本发明涉及药物化学领域，具体涉及一种新型苯甲酰胺类化合物或其药学上可接受的盐，其制备方法，以及含有这类化合物的药物组合物及其在制备抗肿瘤药物中的应用。
• 一种2-氨基噻唑类化合物
  申请人：正大天晴药业集团股份有限公司

  公开号：CN103130792B

  公开（公告）日：2016-05-04

  本发明涉及药物化学技术领域，具体而言涉及一种2-氨基噻唑类化合物或其药学上可接受的盐，其制备方法，以及含有这类化合物的药物组合物及其在制备抗肿瘤药物中的应用。
• Novel pyrazolo[1,5-a]pyridines as PI3K inhibitors: variation of the central linker group
  作者：Jackie D. Kendall、Andrew J. Marshall、Anna C. Giddens、Kit Yee Tsang、Maruta Boyd、Raphaël Frédérick、Claire L. Lill、Woo-Jeong Lee、Sharada Kolekar、Mindy Chao、Alisha Malik、Shuqiao Yu、Claire Chaussade、Christina M. Buchanan、Gordon W. Rewcastle、Bruce C. Baguley、Jack U. Flanagan、William A. Denny、Peter R. Shepherd

  DOI：10.1039/c3md00221g

  日期：——

  As part of our investigation into the pyrazolo[1,5-a]pyridines as novel PI3K inhibitors, we report a range of analogues where the central linker portion of the molecule was varied while retaining the pyrazolo[1,5-a]pyridine and arylsulfonyl or arylcarbonyl groups. Isostere generating software BROOD was used to assist with producing ideas. The isoform selectivity of the compounds varied from pan-PI3K for compound 41 to p110α-selective for compound 58 or p110δ-selective for compound 57. The latter two compounds varied only in their sulphur oxidation state.

  作为我们对吡唑并[1,5-a]吡啶作为新型PI3K抑制剂的研究的一部分，我们报告了一系列类似物，其中分子的中央连接部分进行了变化，同时保留了吡唑并[1,5-a]吡啶和芳基磺酰或芳基羰基基团。我们使用了异构体生成软件BROOD来帮助生成创意。这些化合物的同种型选择性从化合物41的全PI3K到化合物58的p110α选择性，或者化合物57的p110δ选择性。这两个后者化合物仅在其硫氧化态上有所不同。
• [EN] NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES<br/>[FR] NOUVEAUX COMPOSÉS BIFONCTIONNELS QUI INHIBENT LES PROTÉINES KINASES ET LES HISTONES DÉSACÉTYLASES
  申请人：4SC AG

  公开号：WO2009063054A1

  公开（公告）日：2009-05-22

  The present invention relates to a bifunctional compound of formula I or its pharmaceutically acceptable salts or solvates A-L-B (I) wherein A is a histone deacetylase (HDAC) inhibitory moiety, L is a single bond or a linker group and B is a protein kinase inhibitory moiety. The bifunctional compound according to formula (I) is useful for the treatment of malignant and non-malignant neoplasia and diseases related to abnormal cell growth.

  本发明涉及公式I的双功能化合物或其药用可接受的盐或溶剂A-L-B（I），其中A是组蛋白去乙酰化酶（HDAC）抑制基团，L是单键或连接基团，B是蛋白激酶抑制基团。根据公式（I）的双功能化合物可用于治疗恶性和非恶性肿瘤以及与异常细胞生长相关的疾病。
• NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES
  申请人：Bar Thomas

  公开号：US20110065734A1

  公开（公告）日：2011-03-17

  The present invention relates to a bifunctional compound of formula I or its pharmaceutically acceptable salts or solvates A-L-B (I) wherein A is a histone deacetylase (HDAC) inhibitory moiety, L is a single bond or a linker group and B is a protein kinase inhibitory moiety. The bifunctional compound according to formula (I) is useful for the treatment of malignant and non-malignant neoplasia and diseases related to abnormal cell growth.

  本发明涉及一种式I的双功能化合物或其药学上可接受的盐或溶剂A-L-B(I)，其中A是组蛋白去乙酰化酶（HDAC）抑制基团，L是单键或连接基团，B是蛋白激酶抑制基团。根据式（I）的双功能化合物对于治疗恶性和非恶性肿瘤以及与异常细胞生长相关的疾病非常有用。